Clobazam (Onfi) vs Midazolam (Nayzilam)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Clobazam (Onfi)

Marketed by Lundbeck LLC and partners

Approved in Epilepsysmall molecule
Reliable signal

NCT00518713 · Phase 3 · completed

The study randomly assigned 238 participants to low-, medium-, or high-dose clobazam or placebo, with participants, care providers, and investigators masked to treatment. Its clinical primary endpoint—percent reduction in drop seizures—was statistically better than placebo for all three doses, supporting a strong evidence grade.

Reported efficacy

Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) (met)

Result source: NCT00518713

Midazolam (Nayzilam)

Marketed by UCB

Approved in Epilepsysmall molecule
Reliable signal

NCT01390220 · Phase 3 · terminated

This was a randomized, triple-blind, placebo-controlled trial in 201 patients, and the primary outcome, control of a seizure cluster with no recurrence, was reached significantly more often with midazolam than with placebo (72 of 134 patients vs 23 of 67, p=0.011).

Reported efficacy

Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67 (met)

Result source: NCT01390220

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointClobazam (Onfi)Midazolam (Nayzilam)
Seizure frequency, % change—Not reported—Not reported
50% responder rate—Not reported—Not reported
Seizure freedom—Not reported54.8% vs 38.7%+16.1 vs placebowk 0.04 · n 31NCT01999777

Seizure frequency, % change

Clobazam (Onfi)
—Not reported
Midazolam (Nayzilam)
—Not reported

50% responder rate

Clobazam (Onfi)
—Not reported
Midazolam (Nayzilam)
—Not reported

Seizure freedom

Clobazam (Onfi)
—Not reported
Midazolam (Nayzilam)
54.8% vs 38.7%+16.1 vs placebowk 0.04 · n 31NCT01999777
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Clobazam (Onfi): 4 of 4 rows · Midazolam (Nayzilam): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricClobazam (Onfi)Midazolam (Nayzilam)
Dropout rate
30.5%high dosea
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 4 more results
13.8%low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
27.4%medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
29.6%
NCT01160770 · Phase 3 · monotherapy
10%
NCT03371836 · Phase 4 · registry result, not featured evidence
—5 mg + 5 mgb
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 4 more results
—5 mg only
NCT01390220 · Phase 3 · Epilepsy · phase 3
—USL261 CP
NCT01390220 · Phase 3 · Epilepsy · phase 3
31.2%USL261 TDP
NCT01390220 · Phase 3 · Epilepsy · phase 3
0%
NCT01999777 · Phase 3 · monotherapy
Discontinued due to AEs
—high dosea
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 4 more results
—low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
—medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
3.7%
NCT01160770 · Phase 3 · monotherapy
—
NCT03371836 · Phase 4 · registry result, not featured evidence
—5 mg + 5 mgb
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 4 more results
—5 mg only
NCT01390220 · Phase 3 · Epilepsy · phase 3
—USL261 CP
NCT01390220 · Phase 3 · Epilepsy · phase 3
5.8%USL261 TDP
NCT01390220 · Phase 3 · Epilepsy · phase 3
—
NCT01999777 · Phase 3 · monotherapy
Serious AEs
8.5%high dosea
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 4 more results
5.2%low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
9.7%medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
43.1%
NCT01160770 · Phase 3 · monotherapy
—
NCT03371836 · Phase 4 · registry result, not featured evidence
0%5 mg + 5 mgb
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 4 more results
0%5 mg only
NCT01390220 · Phase 3 · Epilepsy · phase 3
—USL261 CP
NCT01390220 · Phase 3 · Epilepsy · phase 3
0.7%USL261 TDP
NCT01390220 · Phase 3 · Epilepsy · phase 3
0%
NCT01999777 · Phase 3 · monotherapy
Most frequent reported AEs
high dosea
somnolence 25.4% (placebo 11.9%)
lethargy 15.3% (placebo 5.1%)
aggression 13.6% (placebo 5.1%)
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 3 more results
low dose
pyrexia 17.2% (placebo 3.4%)
somnolence 15.5% (placebo 11.9%)
lethargy 10.3% (placebo 5.1%)
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
medium dose
somnolence 24.2% (placebo 11.9%)
drooling 12.9% (placebo 3.4%)
upper respiratory tract infection 12.9% (placebo 10.2%)
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
upper respiratory tract infection 28.1%
pyrexia 18%
somnolence 16.9%
NCT01160770 · Phase 3 · monotherapy
5 mg + 5 mgb
nasal discomfort 16.3% (placebo 7.3%)
somnolence 9.3% (placebo 9.8%)
throat irritation 7% (placebo 2.4%)
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 3 more results
5 mg only
somnolence 9.9% (placebo 9.8%)
headache 6.6% (placebo 0%)
nasal discomfort 5.5% (placebo 7.3%)
NCT01390220 · Phase 3 · Epilepsy · phase 3
nasal discomfort 16.1% (placebo 7.3%)
somnolence 9.6% (placebo 9.8%)
lacrimation increased 6.8% (placebo 2.4%)
NCT01390220 · Phase 3 · Epilepsy · phase 3
nasal discomfort 16.1% (placebo 16.1%)
nausea 9.7% (placebo 3.2%)
throat irritation 9.7% (placebo 9.7%)
NCT01999777 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.
  2. bPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Clobazam (Onfi)

Drop Seizure -41.2% (n=53) vs -12.1% (n=57) placebo @ 12wklow dose
percent change · % of baseline
Maintenance
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 41.2 Percent Reduction as posted
show 11 more results
-49.4% (n=58) vs -12.1% (n=57) placebo @ 12wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 49.4 Percent Reduction as posted
-68.3% (n=49) vs -12.1% (n=57) placebo @ 12wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 68.3 Percent Reduction as posted
-47.8% (n=53) vs -18.6% (n=57) placebo @ 4wk*low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 47.8 Percent reduction as posted
-58.9% (n=58) vs -18.6% (n=57) placebo @ 4wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 58.9 Percent reduction as posted
-71% (n=49) vs -18.6% (n=57) placebo @ 4wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 71 Percent reduction as posted
-44.1% (n=52) vs -21.1% (n=47) placebo @ 8wk*low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 44.1 Percent reduction as posted
-38.8% (n=53) vs -21.1% (n=47) placebo @ 8wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 38.8 Percent reduction as posted
-64.9% (n=44) vs -21.1% (n=47) placebo @ 8wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 64.9 Percent reduction as posted
-31.8% (n=51) vs 0.1% (n=44) placebo @ 12wk*low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 31.8 Percent reduction as posted
-56% (n=46) vs 0.1% (n=44) placebo @ 12wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 56 Percent reduction as posted
-68% (n=42) vs 0.1% (n=44) placebo @ 12wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 68 Percent reduction as posted
CGI-I 2 score
absolute value · score
No placebo or comparator arm
NCT03371836 · Phase 4 · registry result, not featured evidence

Midazolam (Nayzilam)

Seizure Cluster Treatment Success 53.7% (n=134) vs 34.3% (n=67) placebo
event count · % of participants
NCT01390220 · Phase 3 · Epilepsy · phase 3 · converted to % from 72 Participants as posted
Seizure Recurrence 4h 38.1% (n=134) vs 59.7% (n=67) placebo
event count · % of participants
NCT01390220 · Phase 3 · Epilepsy · phase 3 · converted to % from 51 Participants as posted
Seizure Recurrence 24 h 37.3% (n=134) vs 46.3% (n=67) placebo
event count · % of participants
NCT01390220 · Phase 3 · Epilepsy · phase 3 · converted to % from 50 Participants as posted
Time to Next Seizure NA vs 12.1 placebo hours
absolute value · hours
NCT01390220 · Phase 3 · Epilepsy · phase 3
Seizure-free 54.8% (n=31) vs 38.7% (n=31) placebo @ 0.04wk
responder rate · % of participants
NCT01999777 · Phase 3 · monotherapy · converted to % from 17 Participants as posted
Time to First Seizure NA vs 3.9 placebo hours
absolute value · hours
NCT01999777 · Phase 3 · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clobazam (Onfi)'s landscape · Midazolam (Nayzilam)'s landscape